Praxis Precision Medicines Inc

Stock Chart, Company Information, and Scan Results

$169.95(as of Oct 20, 12:31 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Praxis Precision Medicines Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$169.95
Ticker SymbolPRAX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees116
CountyUSA
Market Cap$4,021.3M
EBIDTA-271.4M
10-Day Moving Average78.02
P/E Ratio-16.25
20-Day Moving Average64.79
Forward P/E Ratio0.00
50-Day Moving Average52.81
Earnings per Share-12.41
200-Day Moving Average51.16
Profit Margin-Infinity%
RSI95.39
Shares Outstanding21.0M
ATR15.66
52-Week High205.89
Volume4,431,426
52-Week Low26.70
Most Recent Support Level50.56
Book Value404.2M
Most Recent Resistance Level205.89
P/B Ratio10.09
Upper Keltner100.03
P/S Ratio525.43
Lower Keltner29.55
Debt-to-Equity Ratio100.03
Next Earnings Date11/05/2025
Cash Surplus108.8M
Next Ex-Dividend DateUnknown

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc In Our Stock Scanner

As of Oct 20, 2025
example chart graphic
Scan Name: Most Volatile StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.